Replies to post #143598 on NanoViricides Inc. (NNVC)

[Its_lose_not_loose]

It's not just you. The company (NNVC) is merely hypothesizing about the effectiveness of their drugs, using their own data/criteria, not really reporting on factual data presented by actual testing entities. It's just the same old song and dance, my friend.

Human coronavirus NL63 (hCoV-NL63) uses the same ACE2 receptor as the SARS-CoV-2 that causes CoVID-19. Both in terms of its clinical pathology, and its receptor usage, it is known to be very similar to SARS-CoV-2, except much milder. Therefore the Company believes hCoV-NL63 is a good surrogate model for therapeutics development against SARS-CoV-2. H-CoV-Nl63 can be studied in a BSL2 lab whereas SARS-CoV-2 currently requires a BSL3 or BSL4 facility.

The Company also found that the same two nanoviricides drug candidates were highly effective against another coronavirus, namely hCoV-229E, that causes seasonal common colds in humans. These nanoviricides drug candidates were several-fold more effective than favipravir in this human common colds coronavirus as well. HCoV-229E uses the APN (Aminopeptidase-N) membrane protein on human cells as its receptor to enter cells, different from hCoV-NL63 and SARS-CoV-2.

The fact that these nanoviricides anti-coronavirus drug candidates are highly effective against two distinctly different coronaviruses that use different cellular receptors is very significant, the Company believes. Specifically, it provides confidence to the Company and rational basis to scientists that even if the SARS-CoV-2 coronavirus mutates, the nanoviricides can be expected to continue to remain effective.

Importantly, nanoviricides are designed to act by a novel mechanism of action, trapping the virus particle like the "Venus-fly-trap" flower does for insects. Antibodies, in contrast, only label the virus for other components of the immune system to take care of. It is well known that the immune system is not functioning properly at least in severe COVID-19 patients.

In addition, it is generally thought that SARS-CoV-2 may be able to escape antibodies being developed as drugs. Antibodies are known to become ineffective upon viral mutations.

Moreover, there is a significant scientific debate about whether vaccines may be able to produce protective immunity against SARS-CoV-2.

Thus, the Company believes that the nanoviricides drug candidates it has developed are potentially superior to favipravir and are expected to warrant human clinical studies. Oral favipravir and infusion of remdesivir are two anti-viral drugs in clinical trials for the treatment of COVID-19.

Prior to filing for human clinical studies, NanoViricides plans on conducting studies to further determine the effectiveness against SARS-CoV-2, and perform certain animal studies for safety/toxicology.

The Company believes that broad-spectrum anti-coronavirus drugs such as its nanoviricides drug candidates are expected to provide the ideal solution for combatting COVID-19, provided that the candidates show effectiveness in human clinical trials.